DE60141636D1 - Phospholipidderivate von valproinsäure und ihre kombinationen - Google Patents

Phospholipidderivate von valproinsäure und ihre kombinationen

Info

Publication number
DE60141636D1
DE60141636D1 DE60141636T DE60141636T DE60141636D1 DE 60141636 D1 DE60141636 D1 DE 60141636D1 DE 60141636 T DE60141636 T DE 60141636T DE 60141636 T DE60141636 T DE 60141636T DE 60141636 D1 DE60141636 D1 DE 60141636D1
Authority
DE
Germany
Prior art keywords
valproic acid
combinations
phospholipid derivatives
compounds
phospholipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60141636T
Other languages
English (en)
Inventor
Alexander Kozak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DPHARM Ltd
D Pharm Ltd
Original Assignee
DPHARM Ltd
D Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DPHARM Ltd, D Pharm Ltd filed Critical DPHARM Ltd
Application granted granted Critical
Publication of DE60141636D1 publication Critical patent/DE60141636D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
DE60141636T 2000-07-12 2001-07-10 Phospholipidderivate von valproinsäure und ihre kombinationen Expired - Lifetime DE60141636D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/614,271 US6313106B1 (en) 1995-06-07 2000-07-12 Phospholipid derivatives of valproic acid and mixtures thereof
PCT/IL2001/000629 WO2002007669A2 (en) 2000-07-12 2001-07-10 Phospholipid derivatives of valproic acid and mixtures thereof

Publications (1)

Publication Number Publication Date
DE60141636D1 true DE60141636D1 (de) 2010-05-06

Family

ID=24460534

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60141636T Expired - Lifetime DE60141636D1 (de) 2000-07-12 2001-07-10 Phospholipidderivate von valproinsäure und ihre kombinationen

Country Status (20)

Country Link
US (2) US6313106B1 (de)
EP (1) EP1315506B1 (de)
JP (1) JP5140224B2 (de)
KR (1) KR100801213B1 (de)
CN (1) CN100536851C (de)
AT (1) ATE461697T1 (de)
AU (2) AU2001270962B8 (de)
BR (1) BR0112337A (de)
CA (1) CA2415354C (de)
CY (1) CY1110113T1 (de)
CZ (1) CZ305745B6 (de)
DE (1) DE60141636D1 (de)
DK (1) DK1315506T3 (de)
ES (1) ES2343403T3 (de)
HU (1) HU229320B1 (de)
IL (1) IL153147A0 (de)
MX (1) MXPA03000326A (de)
NZ (1) NZ522788A (de)
PT (1) PT1315506E (de)
WO (1) WO2002007669A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313106B1 (en) * 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
US6518311B2 (en) * 1997-07-09 2003-02-11 D-Pharm Ltd. Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
US7582678B2 (en) 1997-07-09 2009-09-01 D-Pharm Limited Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
US7217696B2 (en) 2002-02-28 2007-05-15 A & D Bioscience, Inc. Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
US20050255038A1 (en) * 2002-04-12 2005-11-17 A And D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof
EP1549323A2 (de) * 2002-05-07 2005-07-06 A & D Bioscience, Inc. Konjugate mit einem wirkstoff für das zentrale nervensystem
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
US20050170063A1 (en) * 2004-01-29 2005-08-04 Lalit Chordia Production of powder and viscous material
GB2442365B (en) * 2005-03-24 2010-01-20 John Marcell Davis Methods of determining compounds useful in the treatment of bipolar disorders
US20080234213A1 (en) * 2005-09-02 2008-09-25 Matthias Wabl Oncogenic regulatory RNAs for diagnostics and therapeutics
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
KR200451744Y1 (ko) * 2008-10-10 2011-01-10 이종희 휴대용 운동기구
EP2882427A2 (de) * 2012-05-08 2015-06-17 Cellixbio Private Limited Zusammensetzungen und verfahren zur behandlung neurologischer erkrankungen
CN104230981B (zh) * 2013-06-20 2016-05-18 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的制备方法
US20180169035A1 (en) * 2016-03-16 2018-06-21 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition
CN108659037B (zh) * 2017-03-31 2022-01-11 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的多晶型物及制备方法
CN108659038B (zh) * 2017-03-31 2022-01-11 江苏恩华药业股份有限公司 1-硬脂酰-2-丙戊酰-sn-甘油-3-磷脂酰胆碱的多晶型物及制备方法
KR101864085B1 (ko) * 2017-09-22 2018-06-01 동아대학교 산학협력단 발프로산 유도체, 이의 제조방법 및 이를 포함하는 항경련제
CN110407867A (zh) * 2018-04-28 2019-11-05 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的新晶型及其制备方法
CN114344303B (zh) * 2022-01-13 2023-05-09 江苏海洋大学 一种新型精神药物固体分散体及制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654370A (en) 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4988731A (en) 1979-08-20 1991-01-29 Abbott Laboratories Sodium hydrogen divalproate oligomer
US5212326A (en) 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
US4558070A (en) 1983-10-26 1985-12-10 Abbott Laboratories Acid salts of valproic acid
CA1260393A (en) * 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
IT1201149B (it) 1987-01-14 1989-01-27 Indena Spa Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
ATE151467T1 (de) 1987-11-30 1997-04-15 Univ Iowa Res Found Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
DE3801587A1 (de) 1988-01-21 1989-08-03 Hoechst Ag Neue aminosaeureglyceride, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
JPH04503957A (ja) 1989-03-07 1992-07-16 ジェネンテク，インコーポレイテッド 脂質とオリゴヌクレオチドの共有結合コンジュゲート
JPH03133987A (ja) 1989-10-18 1991-06-07 Kowa Yakuhin Kogyo Kk ２‐マイトマイシンｃ‐スクシニル‐１，３‐ジパルミトイルグリセロールおよびその製造法
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
CH679856A5 (de) 1990-07-04 1992-04-30 Lonza Ag
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
CA2112803A1 (en) 1991-07-12 1993-01-21 Karl Y. Hostetler Antiviral liponucleosides: treatment of hepatitis b
US6015834A (en) 1992-10-20 2000-01-18 Toronto Neuroprotection Group In vivo treatment of mammalian cells with a cell membrane permeant calcium buffer
IL105244A (en) 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US6413949B1 (en) 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US6313106B1 (en) * 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
IL121268A0 (en) * 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
KR100301803B1 (ko) 1998-06-05 2001-09-22 김영환 박막트랜지스터 및 그의 제조방법

Also Published As

Publication number Publication date
CN1774252A (zh) 2006-05-17
EP1315506A4 (de) 2005-03-30
PT1315506E (pt) 2010-05-17
HU229320B1 (en) 2013-10-28
WO2002007669A3 (en) 2003-01-09
AU7096201A (en) 2002-02-05
ES2343403T3 (es) 2010-07-30
DK1315506T3 (da) 2010-05-31
CZ305745B6 (cs) 2016-03-02
CA2415354C (en) 2009-09-29
ATE461697T1 (de) 2010-04-15
US6313106B1 (en) 2001-11-06
WO2002007669A2 (en) 2002-01-31
AU2001270962B8 (en) 2006-08-10
CA2415354A1 (en) 2002-01-31
BR0112337A (pt) 2004-06-08
EP1315506A2 (de) 2003-06-04
AU2001270962B2 (en) 2006-03-16
KR100801213B1 (ko) 2008-02-05
JP5140224B2 (ja) 2013-02-06
US20040033987A1 (en) 2004-02-19
IL153147A0 (en) 2003-06-24
HUP0302635A2 (hu) 2003-11-28
CN100536851C (zh) 2009-09-09
MXPA03000326A (es) 2004-12-13
KR20030034099A (ko) 2003-05-01
CZ200386A3 (cs) 2003-06-18
EP1315506B1 (de) 2010-03-24
JP2004509854A (ja) 2004-04-02
CY1110113T1 (el) 2015-01-14
NZ522788A (en) 2005-04-29
HUP0302635A3 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
EP1673078A4 (de) Benzylether- und benzylamino-beta-sekretase-hemmer zur behandlung von alzheimer-krankheit
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
SE0301009D0 (sv) Novel compounds
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
GB0111186D0 (en) Novel compounds
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE267816T1 (de) Tan-1057 derivate
DE60329326D1 (de) Tace inhibitoren
GEP20053590B (en) Phenyl Heterocyclyl Ether Derivatives as Serotonin Re-Uptake Inhibitors
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
DE60209886D1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
SE0001631D0 (sv) New use
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine
DE60108241D1 (de) Felabamat-derivate zur behandlung von neuropathischem schmerz
ATE480638T1 (de) Nukleinsäuremoleküle aus peritrophin von flöhen, proteine und ihre anwendungen
ATE355834T1 (de) Verwendung von 4-oxo-butansäure derivaten zur behandlung der entzündung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition